Bempedoic acid in older adults: new data
Authors:
Martin Šatný
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
AtheroRev 2026; 11(2): 109-111
Category:
Reviews
Overview
Lowering of LDL-cholesterol (LDL-C) levels remains an effective strategy for preventing atherosclerotic cardiovascular (CV) events in adults aged ≥ 75 years. In clinical practice, however, lipid-lowering treatment in older adults is complicated by comorbidities, polypharmacy and a higher prevalence of statin intolerance. Bempedoic acid (BA) is an oral ATP-citrate lyase inhibitor with proven LDL-C lowering and CV benefit in statin-intolerant patients. New age-specific analyses show that the LDL-C-lowering effect of BA is preserved in patients aged ≥ 75 years, i. e. placebo-corrected LDL-C decreased by 22.6 %, with no evidence of heterogeneity in the MACE-4 (compared to younger subjects). These findings support BA as a treatment option in appropriately selected older patients.
Keywords:
elderly – bempedoic acid – dyslipidemia – statin intolerance – LDL cholesterol
Sources
- Gencer B, Marston NA, Im K et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020; 396(10263): 1637–1643. Dostupné z DOI: <http://doi 10.1016/S0140–6736(20)32332–1>.
- Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388(15): 1353–1364. Dostupné z DOI: (http://doi 10.1056/NEJMoa2215024>.
- Mach F, Koskinas KC, Roeters van Lennep JE et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46(42): 4359–4378. Dostupné z DOI: <http://doi 10.1093/eurheartj/ehaf190>.
- Mukherjee D, Nicholls SJ, Lincoff AM et al. Efficacy and safety of bempedoic acid in patients ≥75 years: analysis of CLEAR Outcomes. J Am Coll Cardiol 2025; 85(12 Suppl): 2631. Dostupné z DOI: <http://doi 10.1016/S0735–1097(25)03115–8>.
- Mancini GBJ, Lincoff AM, Goldberg AC et al. Efficacy and safety of bempedoic acid in patients aged ≥75 years stratified by varying statin exposure: results from phase 3 studies of bempedoic acid. J Am Heart Assoc 2026; 15(13): e047897. Dostupné z DOI: <http://doi 10.1161/JAHA.125.047897>.
- Bittner V, Linnebur SA, Dixon DL et al. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: an expert clinical consensus from the National Lipid Association and the American Geriatrics Society. J Clin Lipidol 2025; 19(2): 215–237. Dostupné z DOI: <http://doi 10.1016/j.jacl.2024.09.005>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2026 Issue 2
Most read in this issue
- Kardiovaskulární prevence v každodenní praxi
- Consensus on the treatment of hyperuricemia in individuals at high cardiovascular risk – update 2025: brief summary
- The level of control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in the routine clinical practice of primary care physicians: results of the BEAT study
- Semaglutide in the 2026 European Society of Cardiology guidelines